The Max Foundation

Resources available through Max for CML patients in LMICs

May 2024

We are on a mission to **accelerate health equity.**

We do this by delivering medication, technology, and services to patients facing cancer and other critical illnesses, focusing our energy on those no one else is helping.

Our **vision** is a world…

where all people can **access** high-impact medicines,

where **geography is not destiny**, and

where everyone can strive for health with **dignity and hope.**

From Max to Raul to Hisham to Rose

1997

2001

2016

2017

2023



Reaching 100,000 Patients over 26 years

The Max Foundation

Impact of GIPAP & CML Program

"Our analysis showed that GIPAP patients had a 5-year survival rate of 89% which compares favorably to survival in high income countries despite the challenges of delivering cancer care in LMICs. About 63,000 GIPAP patients in 93 countries received over 71 million defined daily doses of imatinib between 2001 and 2014."

EClinicalMedicine. 2020 Jan 26;19:100257. doi: 10.1016/j.eclinm.2020.100257. PMID: 32140674; PMCID: PMC7046500.



The Max Foundation

2023 CML Program

Overview and Scope

30,543
patients

494
physicians

117
ship to locations

6
medicines

77
countries

92 hospitals

3 MOH

2 NGOs

20 pharmacies

The Max Foundation

Treatments Available In Our CML Program

1st & 2nd Line

- Glivec (imatinib)
- Bosulif (bosutinib)
- Sprycel (dasatinib)
- Tasigna (nilotinib)

3rd Line

- Iclusig (ponatinib)
- Scemblix (asciminib)

Sub-Saharan Africa: Treatment Access

1st, 2nd & 3rd Line Access

- Benin, Burkina Faso, Burundi, Cameroon, Central Africa Republic, Democratic Republic of Congo, Republic of Congo, Cote d'Ivoire, Eswatini, Ethiopia, Gabon, Ghana, Guinea, Kenya, Madagascar, Malawi, Mali, Mozambique, Niger, Nigeria, Rwanda, Senegal, Seychelles, Sierra Leone, Tanzania, Togo, Uganda, Zambia, Zimbabwe

Eastern Europe/Central Asia: Treatment Access

1st, 2nd & 3rd Line Access

- Armenia, Georgia, Moldova, Mongolia, Tajikistan, Uzbekistan, Kyrgyzstan

1st, & 3rd Line Access

- Belarus,* Azerbaijan, Kazakhstan*

3rd-line Access

- Estonia, Latvia, Lithuania, Macedonia, Republic of Serbia

- *new enrollment closed for 1st line



Latin America: Treatment Access

1st, 2nd & 3rd Line Access

- Bahamas, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Nicaragua, Paraguay, Saint Lucia, Surinam, Venezuela

1st & 2nd Line Access

- Bolivia

1st & 3rd Line Access

- Dominican Republic*

1st Line

- Argentina*, Chile*, Ecuador*, Mexico*, Peru*

3rd Line

- Brazil*

*new enrollment closed for 1st line or 3rd line

Asia Pacific & South Asia Treatment Access

1st, 2nd & 3rd Line Access

- Cambodia, Bhutan, East Timor, Fiji, Laos, Papua New Guinea, Philippines**, Solomon Islands, Nepal and Vanuatu

1st & 3rd Line Access

- India*, Sri Lanka**

*new enrollment closed 1st and 3rd line

**new enrollment closed for 1st line

Diagnostic Testing
Access to PCR

Africa

- Benin, Burundi, Cote d'Ivoire, Democratic Republic of Congo, Ethiopia, Ghana, Kenya, Malawi, Mozambique, Niger, Republic of Congo, Rwanda, Senegal, Seychelles, Tanzania, Togo, Uganda, Zambia and Zimbabwe

Asia Pacific, Eastern Europe & Central Asia

- Bhutan, Cambodia, East Timor, Fiji, Laos, Papua New Guinea, Philippines, Armenia, Georgia, Kyrgyzstan, Mongolia and Tajikistan

Latin America

- Bahamas, Bolivia, Dominican Republic, El Salvador, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Paraguay

South Asia

- India, Nepal

TFR Support Program
Overview

- Program open in six countries: India, Paraguay, Armenia, Honduras, Kenya, and Georgia
- 56 patients in the program/43 active cases
- 13 closed cases (76% success rate – 24% failure)

- Of the 43 active cases:
  - 36 patients completed 6 months
  - 6 patients completed 2 years (24 months)
  - 3 patients completed 2.5 years (30 months)

The Max Foundation

Last Mile Services
Transportation Assistance

Africa

- Ethiopia, Nigeria, Kenya, Zimbabwe

Asia Pacific

- Malaysia, Philippines, Thailand, Cambodia

Latin America

- Argentina, Bolivia, Dominican Republic, Guatemala, Mexico, Paraguay, Peru, Venezuela

South Asia

- India

The Max Foundation

Day by Day

Adherence, support & disease education

- Chile
- Dominican Republic
- Mexico
- Paraguay

The Max Foundation

Patient Organization Collaboration

Africa

- Henzo Kenya, Ethiopia CML Patients Association, Maxcare Foundation Nigeria, CML Zimbabwe Trust

Asia Pacific

- Touched by Max (Philippines) and Max Family Society (Malaysia)

Latin America

- Esperantra (Peru), ASOPALEU (Guatemala), FUNCA (Paragay), Esperanza y Vida (Paraguay), Esperanza y Vida (Ecuador), Fundación Esperanza Nueva (Bolivia) , Celebrando la Vida (Bolivia)

South Asia

- Friends of Max (India)

The Max Foundation

2024 CML Program

Priorities

- Establish a drug access program for CML in Burundi and Eswatini
- Increase access to asciminib
- Grow the TFR support program
- Generic – Pilots
  - Provide access to quality assured generic imatinib
  - Implement Day by Day to support patients receiving generics through their governments

The Max Foundation

Providing innovative treatment where there is none

- Since the introduction of imatinib **22** years ago, there has been unprecedented access to CML treatment in LMICs
- Currently in **57** LMIC countries patients have access to 1st, 2nd and 3rd lines of treatments
- Access to diagnostics, support with transportation costs, and education and adherence programs help patients overcome barriers to access to treatment
- Collaboration between the CMLAN community and Max is key to eliminating barriers to access

"GUANCASCO"
EN LENCA SIGNIFICA:
ENCUENTRO
CANTARANAS
2018